Section Review Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: The current status and future prospects for biological targeted therapies for rheumatoid arthritis

References to Primary Literature

• AKIRA S, HIRANO T, TAGA T, KISHIMOTO I: Biology of multi-functional cytokines: IL-6 and related molecules (IL-1 and TNF). EASES J. (1990) 4:2860–2867.
   Google Scholar
• KIM, KU, KWON OJ, JUE DM: Pro-tumour necrosis factor cleavage factor enzyme in macrophages membrane particulate. Immunology (1993) 83:134–139.
   Google Scholar
• HERZYK DJ, BERGER AE, ALLEN JN, WERNER MD: Sand-wich ELISA formats designed to detect 17 kDa significantly underestimates 35 kDa E-10. J. Immunol. Method (1992) 148:243–254.
   PubMed Web of Science ®Google Scholar
• THORNBERRY NA, PETERSON EP, ZHAO JJ et al: Inactiva-tion of interleukin-113 converting enzyme by peptide (acyloxy) methyl ketones. Biochemistry (1994) 33:3934–3940.
   PubMed Web of Science ®Google Scholar
• LINSLEY PS, GREENE JL, TAN P et al.: Co-expression and functional co-operation of CI'LA4 and CD28 on acti-vated lymphocytes. J. Exp. Med. (1992) 176:1595–1604.
   PubMed Web of Science ®Google Scholar
• COLOTTA F, RE F, MUZIO M: Interleukin-1 type receptor: a decoy target for IL-1 that is regulated by IL-4. Science (1993) 261:472–475.
   PubMed Web of Science ®Google Scholar
• SECKINGER P, VEY E, TURCATTI G, WINGFIELD P, DAYERJM: TNF inhibitor: purification, NH2 terminal amino acid sequence and evidence for anti-inflammatory and itrununomodulatory activities. Eur. J. Immunol. (1990) 20:1167–1174.
   PubMed Web of Science ®Google Scholar
• MACKAY CR, IMHOF BA: Cell adhesion in the immune system. Immunology Today (1993) 14:99–102.
   PubMedGoogle Scholar
• HANAMAIJER R, KOOLWIJK P, LE CLERCQ L: Regulation of metalloproteinase expression in human vein and microvascular endothelial cells. Biochem. J. (1993) 296:803–809.
   PubMed Web of Science ®Google Scholar
• STEVENS CR, BLAKE DR, MERRY P et al.: A comparatixestudy by morphometry of the microvasculature in nor-mal and rheumatoid synovium. Arthritis Rheum. (1991) 34:1508–1513.
   PubMed Web of Science ®Google Scholar
• ANGGARD E: Nitric oxide: mediator, murderer and medicine. Lancet (1994) 343:1199–1206.
   PubMed Web of Science ®Google Scholar
• CHIKANZA IC, GROSSMAN AS: Neuroendocrine immuneresponses to inflammation: the concept of the neuro-endocrine immune loop. Bailliere's Clinical Rheumatology (1996) 10:199–225.
   PubMed Web of Science ®Google Scholar
• FIRESTEIN G, BOYLE DL, YU C et al.: Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum. (1994) 37:644–652.
   PubMed Web of Science ®Google Scholar
• CHIKANZA IC, ROUX-LOMBARD P, DAYER J-M, PANAYIGS: Dysregulated interleukin-1 receptor antagonist pro-tein production in rheumatoid arthritis: pathogenetic Implications. Arthritis Rheum. (1995) 38:642–648.
   PubMed Web of Science ®Google Scholar
• CHIKANZA IC: The neuroendocrine immunology of rheumatoid arthritis. Baillierv's Clinical Rheumatology (1996) 10:273–293.
   PubMed Web of Science ®Google Scholar
• AREND WP, DAYER JM: Inhibition of the production andeffects of interleukin-1 and tumour necrosis alpha in rheumatoid arthritis. Arthritis Rheum. (1995) 38:151–160.
   PubMed Web of Science ®Google Scholar
• ELLIOT MJ, MAINI RN, FELDMAN M et al.: Treatment ofrheumatoid arthritis with chimaeric mAb to TNF-a. Arthritis Rheum. (1993) 36:1681–1690.
   PubMed Web of Science ®Google Scholar
• ELLIOT MJ, MAINI RN, FELDMAN M et al.: Randomiseddouble blind comparison of chimaeric antibody to TNF-a (cA2) in patients with rheumatoid arthritis. Lan-cet (1994) 344:1105–1110.
   PubMed Web of Science ®Google Scholar
• ELLIOT M, MAINI R, FELDMAN M et al.: Repeated therapywith mAb to TNF-a (cA2) in patients with rheumatoid arthritis. Lancet (1994) 344:1125–1127.
   PubMed Web of Science ®Google Scholar
• PALEOLOG EM, TAYLOR PC, HUNT M et al.: Treatment ofrheumatoid arthritis with antibody to TNF-a decreases expression of and shedding of E-selectin. Arthritis Rheum. (1995) 38:S279.
   Web of Science ®Google Scholar
• RANKIN ECC, CHOY EHS, EHRENSTEIN MR et al.: A double-blind, placebo ascending dose trial of the recombinant humanised anti-TNF-a anti-body CDP571 in patients with RA. Arthritis Rheum. (1994) 37:S295.
   Google Scholar
• RANKIN ECC, CHOY EHS, EHRENSTEIN MR et al.: Serologi-cal effects of repeated doses of an engineered anti-INF-a mAb, CDP571 in patients with RA. Arthritis Rheum. (1995) 38:S279.
   Google Scholar
• MALAISE MG, RIBBENS C, KAYE O et al.: A synovial solubleINF-receptor (60 and 80 kDa) level imbalance reflects erosive disease in RA. Arthritis Rheum. (1994) 37:S193.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, MARGOLIES GR, HECK LW et al.: Solubletumour necrosis factor receptor (sTNER): results of a Phase 1 dose-escalation study in patients with RA. Arthritis Rheum. (1994) 37:S295.
   Google Scholar
• GEARING AJH, BECKETT P, CHRISTODOULOU M et al:Processing of tumor necrosis factor alpha precursors by metalloproteinase. Nature (1994) 370:555–557.
   PubMed Web of Science ®Google Scholar
• THIEL M, BARDENHEUER H, POCH G, MADEL C, PETER K:Pentoxyfylline does not act via adenosine receptors in the inhibition of the superoxide anion production of human polymorphonuclear leukocytes. Biochem. Bio-phys. Res. Commun. (1991) 180:53–58.
   PubMed Web of Science ®Google Scholar
• MAKSYMOWYCH WP, AVINA-ZUBIETA A, LUONG MH, RUSSEL AS: An open study of pentoxyf-ylline in the treatment of severe refractory RA. J. Rheumatol. (1995) 22:625–629.
   PubMed Web of Science ®Google Scholar
• BEAVO JA, REISFELD DH: Primary sequence of cyclic nucleotide phosphodiesterase isoenzymes and the de-sign of selective inhibitors. Trends Pharmacol. Sci. (1990) 11:150–161.
   PubMed Web of Science ®Google Scholar
• SEMMLER JH, WACHTEL H, ENDRES S: The specific type IV phosphodiesterase inhibitor rolipram suppresses INF-a production by human mononuclear cells. Int. J. Immunopharmacol. (1993) 15:409–418.
   PubMed Web of Science ®Google Scholar
• SUTTORP N, WEBER U, WELSCH T, SCITUDT C: Role of phosphodiesterase in the regulation of endothelial per-meability in vitro. J. Chn. Invest. (1993) 91:1421–1426.
   PubMed Web of Science ®Google Scholar
• SOMMER N, LOSCHMANN PA, NORTHOFF GH et al.: The anti-depressant rolipram suppresses cytokine produc-tion and prevents autoimmune encephalomyelitis. Na-ture Medicine (1995) 1:244–248.
   PubMed Web of Science ®Google Scholar
• DREVLOW BE, LOVIS R, HAAG MA et al.: Recombinanthuman interleukin-1 receptor type 1 in the treatment of patients with active RA. Arthritis Rheum. (1996) 39:257–265.
   PubMed Web of Science ®Google Scholar
• BESEDOVSKY H, DEL ROY A, SORIUN E, DINARELLO C: ImmunoreguLatory feedback between IL-1 and the glu-cocorticoid hormones. Science (1986) 233:652–666.
   PubMed Web of Science ®Google Scholar
• AREND WP, MALYAK M, SMITH MF et al.: Binding of IL-la, IL-li) and IL-lra by soluble IL-1 receptors and levels of soluble IL-1 receptors by synovial fluid. J. Immunol. (1994) 153:4766–4774.
   PubMed Web of Science ®Google Scholar
• SVENSON M, HANSEN MB, HEEGARD P, ABELL K, BENDTZEN K: Specific binding of IL-10 and IL-lra to human serum: high affinity binding of IL-lra to soluble IL-1 receptor type 1. Cytokine (1993) 5:427–435.
   PubMed Web of Science ®Google Scholar
• POPE RM, DREVLOW BE, CAPEZIO J et al.: Ultra-articularadministration of recombinant human 11–1 receptor type 1 in patients with active RA. In: Biologic Agents in Autoimmune Disease IV. (1996). In Press.
   Google Scholar
• SADOUK M, PELLETIER JP, TARDIF K et al.: Coexpression of IL-1R1 and IL-1R2 in human OA synovial fibroblasts: binding and biological activity is mediated exclusively by type 1 receptor. Arthritis Rheum. (1994) 37:S306.
   Google Scholar
• ARENTD WP, DAYER JM: Cytokines and cytokines inhibi-tors or antagonists in rheumatoid arthritis. Arthritis Rheum. (1990) 33:305–315.
   PubMed Web of Science ®Google Scholar
• FIFtESTEIN GS, BOYLE D, YU C et al.: Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum. (1994) 37:644–652.
   Google Scholar
• LEDSACK ME, PAUL ME, BLOEDOW DC et al.: Subcutane-ous IL-1 receptor antagonist in patients with rheuma-toid arthritis [Abstract]. Arthritis Rheum. (1991) 34:S45.
   Google Scholar
• LEBSACK ME, PAUL CC, MARTINDALE JJ, CATALANO MA: A dose and regimen ranging study of IL-1 receptor antagonist in patients with rheumatoid arthritis [Ab-stract]. Arthritis Rheum. (1993) 36:S39.
   PubMed Web of Science ®Google Scholar
• ROESSLER FJ, ALLEN ED, WILSON JM, HARTMAN JW, DAVIDSON BL: Adenoviral-mediated gene transfer to rabbit synovium in vivo. J. ain. Invest. (1993) 92:1085–1092.
   PubMed Web of Science ®Google Scholar
• HARTMAN JW, DAVIDSON BL, ROESSLER FJ: Genetic modification of synoviocytes in vivo using recombinant adenoviral vectors [Abstract]. Arthritis Rheum. (1993) 36:S64.
   Google Scholar
• BANDARA G, MUELLER GM, GALEA-LAUR1 J et al.: Infraarticular expression of biologically active interleukin-1 receptor antagonist protein by ex-vivo gene transfer. Proc. Natl. Acad. Sci. USA (1993) 90:10764–10768.
   Google Scholar
• HARDING MW, KU G, FAUST T, LAUFFER LL, LIVINGSTONE D: Interleukin-113 converting enzyme inhibition blocks progression of type 2 collagen-induced arthritis in mice. Arthritis Rheum. (1995) 38:S400.
   Web of Science ®Google Scholar
• ISOMAKI P, LUUKKANES R, SAAFt10 R, TOIVAREN P, PUN-NONEN J: II-10 functions as an anti-Inflammatory cy-tokine in rheumatoid arthritis. Arthritis Rheum. (1996) 39:386–395.
   PubMed Web of Science ®Google Scholar
• JOOSTEN LAB, HELSEN MA, VAN DEN BERG WB: Effect ofIL-10 on murine SCR/ arthritis: role of TNF and IL-1 in joint inflammation and cartilage destruction. Arthritis Rheum. (1995) 38:S401.
   Google Scholar
• KUHLMANN F, ROHLIG C, LUKOSCHEK M, LEMMEL EM,HEILIG B: Effects of IL-10 on synovial fluid mononuclear cells of patients with rheumatic diseases. Arthritis Rheum. (1994) 37:5309.
   Google Scholar
• KAVANAUGH AF, DAVIS LS, NICHOLS LA et al.: Treatmentof refractory rheumatoid arthritis with monoclonal antibody to ICAM-1. Arthritis Rheum. (1994) 37:992–999.
   Google Scholar
• KAVANAUGH A, RITA J, MCFARLIN J, NICHOLS L, LIPSKYP: Anti-CD54 (ICAM-1) monoclonal antibody therapy in early RA_ Arthritis Rheum. (1994) 37:S220.
   Google Scholar
• KAVANAUGH A, DAVIS L, NICHOLS L, LIPSKY P: Re-treat-ment of RA patients with an anti-ICAM-1 monoclonal antibody. Arthritis Rheum. (1994) 37:S280.
   Google Scholar
• EDMONDS SE, BLAKE DR, MORRIS CJ, WINYARD PG: AnImaginative approach to synovitis - the role of hypoxic reperfusion damage in arthritis. I Rheum. (1993) 20:26–31.
   Web of Science ®Google Scholar
• SANTOS LL, MORAD EF, HOLDSWORTH SR: Suppressionof adjuvant arthritis by n-bninoethyl-l-ornithine, a ni-tric oxide synthase inhibitor. Arthritis Rheum. (1995) 38:S371.
   Google Scholar
• TRENTHAM DR, DYNESIUS-'rRENTHAM RA, ORAV EJ et al.:Effects of oral administration of type 2 collagen on rheumatoid arthritis. Science (1993) 261:1727–1730.
   Google Scholar
• SLEPER J, KARY S, SORENSON H et al.: Oral type 2 collagentreatment in early RA. A double-blind placebo-control-led, randomised study. Arthritis Rheum. (1996) 39:41–51.
   Google Scholar
• ROSENTHAL M, PLATTNER S: The treatment of rheuma-toid arthritis with OM-8980. j Rheumatol. (1981) 40:228–231.
   Google Scholar
• BRACKERTZ D, VISCHER TL: OM-8980 in rheumatoid arthritis: a six month, double-blind, placebo-controlled study. J. Rheumatol. (1989) 16:19–23.
   PubMed Web of Science ®Google Scholar
• HAUZEUR JP, APPLEBOM T: Double-blind, placebo-con-trolled study of OM-8980 in RA- Rheumatol. Int. (1989) 9:71–76.
   Google Scholar
• VISCHER TA: Double-blind multicentre study of OM-8980 and auranoffin in RA. Ann. Rheum. Dis. (1988) 47:582–587.
   PubMed Web of Science ®Google Scholar
• VERSTRAEN'TEN A, SLLEGHEM A, DEQUEKER J: OM-8980 and d-perticilLamine in the treatment of rheumatoid arthritis: a 12 months double-blind randomised study. Scand. J. Rheumatol. (1990) 19:422–431.
   PubMedGoogle Scholar
• STAINES NA, HARPER N, BE VAN DJ, THOMPSON HSG: Oral tolerance: potential therapy for autoimmune diseases. 8ème Symposium International d'Immunorheumatologie, Monpellier (1992):239–250.
   Google Scholar
• LINSLEY PS, LEDBE IIER JA: The role of CD28 receptorduring T-cell responses to antigen. Ann. Rev. Immunol. (1993) 11:191–212.
   PubMed Web of Science ®Google Scholar
• LINSLEY PS, WALLACE PM, JOHNSON J et al.: Immunosup-pression in vivo by a soluble form of CTLA-4 T-cell activation molecule. Science (1992) 257:792–795.
   PubMed Web of Science ®Google Scholar
• KNOERZER DB, KARR RW, SCHWARTZ BD, MENGLE-GAW LJ: Collagen-induced arthritis in the BB rat; prevention of disease by treatment with CTLA-41g. J. Clin. Invest. (1995) 96:987–993.
   PubMed Web of Science ®Google Scholar
• KHOURY SJ, AKALIN E, CHANDRAKER A et al.: CD28-B7 co-stimulatory blockade by CTLA-4IgG prevents ac-tively induced experimental autoimmune encephalo-myelitis and inhibits Thl but spares Th2 cytokines in the central nervous system. J. Immunol. (1995) 155:4521–4524.
   PubMed Web of Science ®Google Scholar
• WILLIAMS RO, MASON LM, FELDMANN, MAINI R: Synergy between anti-CD4 and anti-TNF in the amelioration of established collagen-induced arthritis. Proc. Natl. Acad. Sci. USA (1994) 9:12762–12766.
   Google Scholar
• JOOSTEN LAB, HELSEN MMA, VAN DE LOO FAJ, VAN DE BERG WB: Anticytokine treatment of established type 2 collagen-induced arthritis in DBA/1 mice: a compara-tive study using anti-TNF-a, anti-IL-10/a and IL-lra. Arthritis Rheum. (1996) 39:797–809.
   PubMed Web of Science ®Google Scholar